Press Releases

Company News
Summary ToggleAcura Pharmaceuticals Announces Settlement of Oxecta(R) Patent Litigation With Par Pharmaceutical and Impax Laboratories
Oct 09, 2013
PALATINE, IL -- (Marketwired) -- 10/09/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into distinct Settlement Agreements with each of Par Pharmaceutical

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on NEXAFED(R) Launch
Sep 18, 2013

Over 2,600 Pharmacies Now Selling the Meth-Resistant Pseudoephedrine Product

Read more

Summary ToggleResearch Confirms New Nasal Decongestant Product Is Highly Meth-Resistant Yet Offers Same Effectiveness as Leading Pseudoephedrine Brand
Sep 03, 2013

Study Published in American Journal of Drug and Alcohol Abuse Shows NEXAFED(R) Significantly Disrupts the Extraction and Conversion of Pseudoephedrine to Methamphetamine, While Demonstrating Bioequivalence to the Leading Pseudoephedrine Brand

Read more

Summary ToggleAcura Pharmaceuticals Announces Top-Line Results of a Clinical Study Assessing Abuse Liability
Aug 26, 2013
PALATINE, IL -- (Marketwired) -- 08/26/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced top-line results from Study AP-ADF-301 (Study 301), a phase II clinical study in 40 recreational drug abusers assessing the abuse liability of snorting a crushed hydrocodone bitartrate with

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2013 Financial Results
Aug 01, 2013
PALATINE, IL -- (Marketwired) -- 08/01/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2013 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Second Quarter 2013 Financial Results Conference Call on August 2, 2013
Jul 26, 2013
PALATINE, IL -- (Marketwired) -- 07/26/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the company plans to report financial results for the second quarter of 2013 following the close of financial markets

Read more

Summary ToggleAcura Pharmaceuticals to Develop Improved NEXAFED(R)
Jul 15, 2013

IMPEDE(R) 2.0 Reduces One-Pot Methamphetamine Yield to Near Zero

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on Partnership With Pfizer
Jul 01, 2013
PALATINE, IL -- (Marketwired) -- 07/01/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that Pfizer Inc. (NYSE: PFE) will expand commercialization of OXECTA® (oxycodone HCl) Tablets CII to health care

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2013 Financial Results
May 02, 2013
PALATINE, IL -- (Marketwired) -- 05/02/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three months ended March 31, 2013 .

Read more

Summary ToggleAcura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013
Apr 22, 2013
PALATINE, IL -- (Marketwired) -- 04/22/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the company plans to report financial results for the first quarter of 2013 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals Awarded U.S. Patent for Abuse Deterrent Drug Formulations
Apr 04, 2013

Further Expands Patent Estate Covering Abuse Deterrent Forms of Opioid Analgesics and Certain Other Active Pharmaceutical Ingredients

Read more

Summary ToggleAcura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective
Mar 15, 2013
PALATINE, IL -- (Marketwire) -- 03/15/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that its universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (SEC) today. The universal shelf registration statement permits the

Read more

Summary ToggleAcura Pharmaceuticals Reaches Key Milestone With Entrance Into Chain Drug Store Market
Mar 05, 2013

KERR DRUG First Chain Drug Store Customer to Stock Nexafed(R) -- Next Generation Cold/Allergy Medicine With Abuse-Deterrent Technology -- Joining the Fight Against Meth Abuse

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Financial Results
Mar 04, 2013
PALATINE, IL -- (Marketwire) -- 03/04/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2012 .

Read more

Summary ToggleAcura Pharmaceuticals to Present at the Cowen Health Care Conference on March 5, 2013
Feb 22, 2013
PALATINE, IL -- (Marketwire) -- 02/22/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse , announced today that the Company will present at the Cowen and Company Health Care Conference at the

Read more

Summary ToggleAcura Pharmaceuticals, Inc. Submits Investigational New Drug Application
Dec 20, 2012

Request to Commence Clinical Investigation

Read more

Summary ToggleAcura Pharmaceuticals Launches Next Generation Cold Medicine to Aid in the Fight Against Meth
Dec 10, 2012

Nexafed(R)'s Abuse-Deterrent Technology Disrupts Conversion of Pseudoephedrine to Dangerous Illegal Drug Methamphetamine Without Compromising Effective Nasal-Congestion Relief

Read more

Summary ToggleAcura Pharmaceuticals Announces Successful Bioequivalent Study for NEXAFED
Nov 20, 2012
PALATINE, IL -- (Marketwire) -- 11/20/12 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today topline results from a clinical study that demonstrates Acura's NEXAFED (pseudoephedrine

Read more

Displaying 109 - 126 of 160 results